Summary

for people ages 50 years and up (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.

Official Title

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration

Keywords

Macular Degeneration Wet Macular Degeneration Ranibizumab abicipar pegol

Eligibility

You can join if…

Open to people ages 50 years and up

  • Diagnosis of age-related macular degeneration in at least 1 eye
  • Best corrected visual acuity of 20/40 to 20/320 in the study eye
  • Best corrected visual acuity of 20/200 or better in the non-study eye

You CAN'T join if...

  • History of vitrectomy, macular surgery, or glaucoma surgery in the study eye
  • Cataract or refractive surgery in the study eye within the last 3 months

Locations

  • University of California at Irvine Gavin Herbert Eye Institute
    Irvine California 92697-4375 United States
  • Retina Associates of Orange County
    Laguna Hills California 92653 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
Links
Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
ID
NCT02462486
Phase
Phase 3
Study Type
Interventional
Last Updated